Inovio Pharmaceuticals Files 8-K
Ticker: INO · Form: 8-K · Filed: Dec 16, 2024 · CIK: 1055726
| Field | Detail |
|---|---|
| Company | Inovio Pharmaceuticals, INC. (INO) |
| Form Type | 8-K |
| Filed Date | Dec 16, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.001, $3.00, $27.6 m, $3.76 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financials, filing
Related Tickers: INO
TL;DR
INOVIO filed an 8-K on 12/12/24 - material agreement and financials.
AI Summary
On December 12, 2024, Inovio Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits. The specific details of the agreement and financial information were not provided in this excerpt.
Why It Matters
This filing indicates significant corporate activity for Inovio Pharmaceuticals, potentially related to new agreements or financial updates that could impact investors.
Risk Assessment
Risk Level: medium — Material definitive agreements and financial filings can introduce new risks or clarify existing ones for investors.
Key Players & Entities
- INOVIO PHARMACEUTICALS, INC. (company) — Registrant
- December 12, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-14888 (filing_id) — SEC File Number
- 33-0969592 (tax_id) — IRS Employer Identification No.
FAQ
What type of material definitive agreement did Inovio Pharmaceuticals enter into?
The filing indicates the entry into a material definitive agreement, but the specific nature of the agreement is not detailed in the provided excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on December 12, 2024.
What is Inovio Pharmaceuticals, Inc.'s state of incorporation?
Inovio Pharmaceuticals, Inc. is incorporated in Delaware.
What is the SEC file number for Inovio Pharmaceuticals?
The SEC file number for Inovio Pharmaceuticals is 001-14888.
What other items are reported in this 8-K filing besides the material agreement?
The filing also reports 'Other Events' and 'Financial Statements and Exhibits'.
Filing Stats: 1,376 words · 6 min read · ~5 pages · Grade level 12.2 · Accepted 2024-12-16 08:25:30
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value INO The Nasdaq Stock Mark
- $3.00 — " Warrants "), at an offering price of $3.00 per share and accompanying warrant. The
- $27.6 m — fering are expected to be approximately $27.6 million, after deducting the underwriting
- $3.76 — mon Stock at an exercise price equal to $3.76 per share, will be immediately exercisa
Filing Documents
- d899983d8k.htm (8-K) — 34KB
- d899983dex11.htm (EX-1.1) — 180KB
- d899983dex41.htm (EX-4.1) — 78KB
- d899983dex51.htm (EX-5.1) — 14KB
- d899983dex991.htm (EX-99.1) — 8KB
- g899983g1214030403908.jpg (GRAPHIC) — 2KB
- g899983g1214030638372.jpg (GRAPHIC) — 5KB
- 0001193125-24-279061.txt ( ) — 527KB
- ino-20241212.xsd (EX-101.SCH) — 3KB
- ino-20241212_lab.xml (EX-101.LAB) — 18KB
- ino-20241212_pre.xml (EX-101.PRE) — 11KB
- d899983d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipates," "believes," "expects," "intends," "projects," "plans," and "future" or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the Offering, such as the expected net proceeds and anticipated closing date. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding the Company's business are described in detail in its SEC filings, including in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 and the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, which are available on the SEC's website at www.sec.gov. Additional information will be made available in other filings that the Company makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and the Company disclaims any obligation to update these statements except as may be required by law. Item9.01
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 1.1 Underwriting Agreement, dated December 12, 2024, by and among Inovio Pharmaceuticals, Inc., Oppenheimer & Co. Inc. and Citizens JMP Securities LLC. 4.1 Form of Warrant. 5.1 Opinion of Cooley LLP. 23.1 Consent of Cooley LLP (included in Exhibit 5.1). 99.1 Press Release. 104 Cover Page Interactive Data File (formatted as inline XBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INOVIO PHARMACEUTICALS, INC. Date: December 16, 2024 /s/ Peter Kies Peter Kies Chief Financial Officer